These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 10979074

  • 21. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
    Muruganandam AV, Bhattacharya SK, Ghosal S.
    Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
    [Abstract] [Full Text] [Related]

  • 22. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study.
    Wright CW, Gott M, Grayson B, Hanna M, Smith AG, Sunter A, Neill JC.
    J Psychopharmacol; 2003 Dec; 17(4):403-8. PubMed ID: 14870952
    [Abstract] [Full Text] [Related]

  • 23. Variability in St. John's wort formulations is an important consideration.
    Kroll DJ, Shaw HS, Wall ME, Oberlies NH.
    Altern Ther Health Med; 2001 Dec; 7(6):21-2. PubMed ID: 11712467
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
    Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M.
    J Am Pharm Assoc (Wash); 2001 Dec; 41(4):560-6. PubMed ID: 11486982
    [Abstract] [Full Text] [Related]

  • 25. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
    Laggner H, Schreier S, Hermann M, Exner M, Mühl A, Gmeiner BM, Kapiotis S.
    Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
    [Abstract] [Full Text] [Related]

  • 26. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort.
    Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bickel U, van der Schyf CJ, Klein J.
    J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454
    [Abstract] [Full Text] [Related]

  • 27. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway.
    Zhou C, Tabb MM, Sadatrafiei A, Grün F, Sun A, Blumberg B.
    J Clin Immunol; 2004 Nov; 24(6):623-36. PubMed ID: 15622447
    [Abstract] [Full Text] [Related]

  • 28. St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
    Kholghi G, Arjmandi-Rad S, Zarrindast MR, Vaseghi S.
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):629-642. PubMed ID: 35294606
    [Abstract] [Full Text] [Related]

  • 29. Measurement of hyperforin a constituent of St. John's wort in plasma by high-performance liquid chromatography.
    Chi JD, Franklin M.
    J Chromatogr B Biomed Sci Appl; 1999 Dec 10; 735(2):285-8. PubMed ID: 10670742
    [Abstract] [Full Text] [Related]

  • 30. Role of hyperforin in the pharmacological activities of St. John's Wort.
    Zanoli P.
    CNS Drug Rev; 2004 Dec 10; 10(3):203-18. PubMed ID: 15492771
    [Abstract] [Full Text] [Related]

  • 31. An in vitro and hydroponic growing system for hypericin, pseudohypericin, and hyperforin production of St. John's wort (Hypericum perforatum CV new stem).
    Murch SJ, Rupasinghe HP, Saxena PK.
    Planta Med; 2002 Dec 10; 68(12):1108-12. PubMed ID: 12494339
    [Abstract] [Full Text] [Related]

  • 32. Effect of St. John's wort on free radical production.
    Hunt EJ, Lester CE, Lester EA, Tackett RL.
    Life Sci; 2001 Jun 01; 69(2):181-90. PubMed ID: 11441908
    [Abstract] [Full Text] [Related]

  • 33. Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.).
    Fourneron JD, Naït-Si Y.
    Phytochem Anal; 2006 Jun 01; 17(2):71-7. PubMed ID: 16634282
    [Abstract] [Full Text] [Related]

  • 34. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G, Schüle C, Baghai T, Kieser M.
    Pharmacopsychiatry; 1998 Jun 01; 31 Suppl 1():54-9. PubMed ID: 9684948
    [Abstract] [Full Text] [Related]

  • 35. Hypericum perforatum, a source of neuroactive lead structures.
    Verotta L.
    Curr Top Med Chem; 2003 Jun 01; 3(2):187-201. PubMed ID: 12570773
    [Abstract] [Full Text] [Related]

  • 36. Safety of St John's wort (Hypericum perforatum).
    Wheatley D.
    Lancet; 2000 Feb 12; 355(9203):576. PubMed ID: 10683029
    [No Abstract] [Full Text] [Related]

  • 37. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
    Wurglics M, Schubert-Zsilavecz M.
    Clin Pharmacokinet; 2006 Feb 12; 45(5):449-68. PubMed ID: 16640452
    [Abstract] [Full Text] [Related]

  • 38. Mechanism of action of St John's wort in depression : what is known?
    Butterweck V.
    CNS Drugs; 2003 Feb 12; 17(8):539-62. PubMed ID: 12775192
    [Abstract] [Full Text] [Related]

  • 39. [The administration of St. John's wort (Hypericum perforatum) in the treatment of depression].
    Koszewska I.
    Psychiatr Pol; 2001 Feb 12; 35(2):199-210. PubMed ID: 11490885
    [Abstract] [Full Text] [Related]

  • 40. St John's wort interaction with digoxin.
    Cheng TO.
    Arch Intern Med; 2000 Sep 11; 160(16):2548. PubMed ID: 10979073
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.